BMPR1A and breast carcinoma: LysMCre control (CTL) and LysMCre myeloid cell–restricted BMPR1a–conditional KO (BMPR1a-cKO) mice were used to examine whether myeloid cell BMP signaling was necessary or sufficient alongside β-glucan trained immunity stimulus to alter mammary carcinoma bone metastasis progression.